Montelukast Arena (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Arena, is a leukotriene receptor antagonist presented as an unknown/unknown for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children who require controller therapy.

GNH USA supplies Montelukast Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene‑modifying agent used in respiratory and allergic conditions. - Asthma: improves control of persistent asthma and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: persistent or intermittent coughing. - Diarrhoea: loose, watery stools. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Allergic reactions: hives, swelling of face or throat, difficulty breathing. - Mood changes: agitation, depression, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Angioedema: rapid swelling of lips, tongue, or eyes. - Stevens‑Johnson syndrome: severe skin blistering and detachment. - Anaphylaxis: life‑threatening systemic allergic response.

Before prescribing Montelukast, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Lactation: assess risk versus benefit for nursing mothers. - Hepatic impairment: monitor liver function in patients with liver disease. - Concomitant asthma therapy: ensure patients continue their rescue inhalers as needed. - Age restrictions: use according to approved pediatric dosing guidelines. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; monitor patients accordingly.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: can decrease therapeutic effect by inducing metabolism.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for mood‑related side effects. - Antihistamines: may increase sedation when combined with sedating agents. - CYP2C9 inhibitors (e.g., fluconazole): could modestly raise montelukast levels. - Warfarin: monitor INR as theoretical interaction exists. - Herbal supplements (e.g., St. John’s wort): may alter drug metabolism.